Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NB-1002
- Development stage
- Discontinued
- Lead developer
- Naia Rare Diseases
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
**NB-1002** is a glucagon-like peptide-2 (GLP-2) receptor agonist developed as an XTEN fusion protein, a recombinant polypeptide engineered by fusing GLP-2 with XTEN technology to extend half-life and improve pharmacokinetics for chronic administration. Initially developed by Amunix, Inc. and licensed to Naia Rare Diseases, it was designed primarily for short bowel syndrome, an orphan gastrointestinal indication, by promoting intestinal adaptation and nutrient absorption. Its development has been discontinued globally.
- Other names
- GLP-2-XTENGLP2-XTENGLP 2-XTEN
02
Targets
GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on NB-1002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NB-1002.